Physician profile
Thamar Perry
NPI 1093218646
$587.58
in general payments reported to CMS, 2019-2025
14 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $58.12 · 2024: $263 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $112.74 | 2023-2024 | Eliquis, Camzyos |
| Inari Medical, INC. | $99.78 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $55.22 | 2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $50.59 | 2025 | Rezdiffra |
| Genentech USA, INC. | $46.33 | 2024 | Xolair |
| Amgen INC. | $40.87 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.88 | 2025 | Lifevest |
| Lilly USA, LLC | $23.24 | 2025 | Jardiance |
| Cardiva Medical, INC. | $23.09 | 2024 | Cardiva Vascade 6/7f Vcs |
| Astrazeneca Pharmaceuticals LP | $21.33 | 2025 | Farxiga |
| Scpharmaceuticals INC. | $20.66 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.58 | 2025 | |
| Lantheus Medical Imaging, INC. | $18.33 | 2024 | |
| Acella Pharmaceuticals, LLC | $16.94 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thamar Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.